We're incredibly honored to collaborate with Bayer | Pharmaceuticals to continue to explore the possibilities of contrast-enhanced MRI to provide radiation-free imaging for patients. Our Indian Wells, California Innovation Center is one of the first global sites to support #Innovation through the QUANTI clinical development program. “We are grateful to Bayer for its partnership and the opportunity to potentially impact the diagnostic pathway for patients.” - Bernadette Greenwood, HALO Chief Research Officer
HALO Precision Diagnostics
Hospitals and Health Care
Menlo Park, California 9,669 followers
Precision diagnostics for early disease detection.
About us
HALO Precision Diagnostics™ changes patient lives and outcomes through early detection of the leading causes of death with precision diagnostics. We accomplish this with a personalized diagnostic ensemble including advanced imaging, genomics, non-invasive liquid biomarkers, and community-based data at scale combined with deep learning algorithms. By optimizing all these solutions under the HALO Diagnostics platform, we provide rapid, precise, actionable results to enable life-changing treatments by physicians for their patients.
- Website
-
https://www.halodx.com/
External link for HALO Precision Diagnostics
- Industry
- Hospitals and Health Care
- Company size
- 201-500 employees
- Headquarters
- Menlo Park, California
- Type
- Privately Held
- Founded
- 2016
- Specialties
- interventional radiology, advanced imaging, prostate cancer treatment, precision medicine, genomics, breast cancer, MRI, dementia, heart disease, lung disease, pet scan, ct scan, neurology, personalized healthcare, men's health, TULSA-PRO, laser focal therapy, focal laser ablation, stroke, and cancer treatment
Locations
-
Primary
Menlo Park, California 94025, US
-
Indian Wells, CA 92210, US
Employees at HALO Precision Diagnostics
-
Brian Axe
Founder/Chief Product Officer, HALO Dx
-
Patrick Githens
Senior Director of Operations
-
Dan Gilbert
Board Director, Halo Precision Diagnostics; Advisor, Motus Ventures
-
John Craighead, Ph.D.
Strategic Biotech CEO/COO | Capital Markets | Corporate Development | Investor Relations | M&A | Culture & Team Building
Updates
-
We’re thrilled to welcome aboard Thomas Slavin as our Chief Scientific Officer. Dr. Slavin will guide scientific operations and innovation while supporting the continued evolution of our advanced imaging and diagnostic offerings.
Thomas P. Slavin, M.D., appointed as Chief Scientific Officer | Press Release
https://www.halodx.com